In the US pharmaceutical industry, there were 43 private equity deals announced in Q2 2023, worth a total value of $12.4bn, according to GlobalData’s Deals Database. The $7.1bn institutional buy-out (ibo) syneos health by Elliott Investment Management, Patient Square Capital and Veritas Capital was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in The US increased by 439% in Q2 2023 compared with the previous quarter’s total of $2.3bn and rose by 316% as compared to Q2 2022. Related deal volume increased by 19% in Q2 2023 versus the previous quarter and was 65% higher than in Q2 2022.
The top-ranked financial advisors supporting these private equity deals in The US in Q2 2023 were Cantor Fitzgerald; Moelis & Co; WBC Holdings with 4, 4, 3 deals respectively.
The top-ranked legal advisorss supporting these private equity deals in The US Q2 2023 were Kirkland & Ellis; Goodwin Procter; Ropes & Gray with 6, 5, 4 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.